SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001346302-21-000072
Filing Date
2021-08-05
Accepted
2021-08-05 07:36:14
Documents
15
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xers-20210805.htm   iXBRL 8-K 36772
2 EX-99.1 exh991q22021earningsrelease.htm EX-99.1 101471
7 xerislpharmrgba11a.jpg GRAPHIC 74582
  Complete submission text file 0001346302-21-000072.txt   428540

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20210805.xsd EX-101.SCH 2153
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20210805_def.xml EX-101.DEF 15449
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20210805_lab.xml EX-101.LAB 29866
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20210805_pre.xml EX-101.PRE 16118
8 EXTRACTED XBRL INSTANCE DOCUMENT xers-20210805_htm.xml XML 11514
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 211146350
SIC: 2834 Pharmaceutical Preparations